Health Cures

Nutritherapies – Multivitamins

### OTHER VITAMINS:

## Vitamin A :

# Vitamin A produces astonishing leukemia cure rate, even without chemotherapy, Posted Thursday, June 10, 2004 by Mike Adams ( http://www.healthranger.org/ )
from http://www.newstarget.com/001123.html

New research conducted at the University of Texas M. D. Anderson Cancer Center shows that vitamin A cures as many as 33% of patients with a rare form of leukemiawithout using chemotherapy. In the study, the vitamin A was being delivered inside “bubbles of fat” to enhance bioavailability. Out of 34 patients participating in the trial, an astonishing 10 remained cancer-free after five years, despite receiving no chemotherapy.

So what’s the real story here? Researchers are calling this form of vitamin A ( http://www.webseed.com/vitamin_A.html ) a “drug,” which seems odd, since it’s just vitamin A. Perhaps they don’t want to admit that a vitamin is better than chemotherapy for curing cancer. And this is definitely a cure — that term is even being used by the researchers here.

To take a group of cancer patients and watch them remain cancer-free for five years is nothing short of astonishing, especially since they were only taking one vitamin. Imagine how well they’d do if they also consumed chlorella (a strong anti-cancer superfood), spirulina (another superfood containing phytochemicals known to destroy breast cancer tumors), graviola (an Amazonian herb known for its powerful ability to destroy cancer cells), licorice root (a more popular anti-cancer herb) and other health-promoting foods and supplements. With the help of this collection of health-promoting substances, the cure rate could have easily risen to 75% or more.

Still, that’s just a guess. Organized medicine isn’t really interested in studying things that don’t generate profits, and herbs and superfoods certainly fall into that category. But it is exciting to see vitamin A having such a dramatic, positive impact on patients with leukemia who might otherwise be subjected to chemotherapy. And perhaps someday these researchers will have the courage to admit that it’s a vitamin, not a drug, that’s working the healing magic here.

——————————————-

## Vitamin B12 :

# Supreme Court Vitamin B Case Could Set New Patent Law, Monday, March 20, 2006
Fox news : http://www.foxnews.com/story/0,2933,188489,00.html

WASHINGTON – B vitamin deficiencies can cause a range of serious health effects, including spinal defects in children born to women with below-normal levels of folic acid and anemia in people not getting enough B12.

That’s why a two-step method of diagnosing those deficiencies that three medical school doctors patented in 1990 has become so widely used. It’s performed tens of millions of times a year, at a cost of just a dollar or two, by laboratory testing companies nationwide.

Now, to the surprise of patent attorneys, a case involving one of those companies that was sued after it stopped paying some royalties, has landed in the Supreme Court, where arguments will be heard Tuesday.

Even more surprising is that the Supreme Court may dredge up a bombshell question not asked when the lower courts considered the case: Have inventors been busy patenting laws of nature, natural phenomena and abstract ideas?

At stake, attorneys on both sides of the case say, are 25 years of patent law and literally tens of thousands of patents on drugs, medical devices, computer software and other inventions. If the court reins in what can be patented, they say, it could be among the most important patent law decisions ever made.

The two-step method covered by patent No. 4,940,658 is straightforward: The level of an amino acid called homocysteine is measured in a patient’s blood or urine and, if elevated, it can be correlated with a deficiency of folic acid, or B12.

The question before the Supreme Court is whether a doctor could infringe the patent “merely by thinking about the relationship” between homocysteine levels and B vitamin deficiencies after looking at a test result.

In 1998, testing company Laboratory Corp. of America Holdings stopped paying some royalties on the patent. The patent’s holders, including Metabolite Laboratories Inc. and Competitive Technologies Inc., sued. LabCorp lost, was ordered to pay about $5 million and then lost again on appeal. It now wants the Supreme Court to reverse the previous judgments.

LabCorp, its attorneys and supporters argue in court filings that the patent gives its owners an effective monopoly over a basic scientific principle or natural phenomenon: high levels of homocysteine suggest deficiencies in two B vitamins.

“If someone observes a correlation between X and Y and then announces he is going to use that correlation in a lab test, is that a patentable process? I think the court is troubled that that sort of correlation would be possible,” said Jack Bierig, a Chicago attorney who filed a friend-of-the-court brief supporting LabCorp on behalf of the American Medical Association and five other medical groups.

Metabolite Laboratories counters that the patent covers a practical application of the discovery made by the inventors when used as part of a diagnostic step.

“The test itself is obvious when you have the correlation. It is the discovery of the correlation that is the real novelty here,” said Mark Lemley, a Stanford University law professor who is helping represent Metabolite Laboratories.

LabCorp originally argued that the patent was overly vague, and that allowed it to use tests, called assays, developed by other companies to measure homocysteine levels. Metabolite Laboratories disagreed. That sort of narrow dispute is the crux of many patent suits and normally wouldn’t grab much attention.
But the Supreme Court asked the federal government to weigh in on the case, specifically asking whether Metabolite Laboratories succeeded in patenting a law of nature, natural phenomenon or abstract idea – all no-no’s under patent law.

“They did pretty much shock everybody,” said Chicago-Kent College of Law professor Lori Andrews, who submitted a friend-of-the-court brief supporting LabCorp.
The Solicitor General’s office replied to the Supreme Court that the question wasn’t asked in the lower courts and thus LabCorp’s isn’t the case to decide it. It recommended the previous judgment be affirmed or the case be dismissed or sent back to the lower courts.

Regardless of the outcome, that the Supreme Court even asked that question guarantees the case’s lasting effect on patents and patent law, attorneys said.

Glenn Beaton, an attorney for Metabolite Laboratories, suggested:
“I think it’s fair to say there will be a sudden surge in claiming unpatentable subject matter because defendants’ lawyers out there are going to see someone on the Supreme Court has a question in their mind whether patents are getting granted on the type of thing when they shouldn’t be.”

Since the original LabCorp ruling, there has been a rush to file patents on “scientific facts” or “mental processes,” he said.
The case is Laboratory Corporation of America Holdings v. Metabolite Laboratories Inc. et al., No. 04-607.

# Vitamin B12 may help prevent bone-wasting disease http://www.nutraingredients.com/news/news-ng.asp?n=58022-vitamin-b-may

11/02/2005 – Vitamin B12 deficiency may be an important modifiable risk factor for osteoporosis, say researchers, identifying the nutrient’s connection to bone health in men for the first time.

Dr Katherine Tucker and colleagues from Tufts University in the US report that both men and women with vitamin B12 levels lower than 148 pM had lower average bone mineral density, a measure of bone quality frequently used to assess risk of fracture.

These differences were significant for men at most hip sites and for women at the spine, even after further adjustment for protein intake and plasma homocysteine, they report in the January issue of the Journal of Bone and Mineral Research (vol 20, issue 1, pp152-8).

“This is the first large scale study of its kind to show an association between low vitamin B12 and low bone mineral density in men and it confirms other reports of this association in women,” said Tucker.

“Our study provides support for a way in which people can actively lower their risk of osteoporosis and help to preserve quality of life.”

Osteoporosis is second only to cardiovascular disease in terms of global healthcare burden, according to the World Health Organisation, and currently affects some 200 million people. The number of sufferers is however set to increase steadily with growing numbers of elderly living longer, and obesity adding extra strain on bones.

Tucker and her colleagues measured bone mineral density and vitamin B12 levels in more than 2,500 men and women participating in the Framingham Osteoporosis Study.

Tucker said that dietary B12 may be important for both men and women in maintaining strong bones. She added: “Some individuals, particularly older people, have difficulty absorbing vitamin B12 from foods, however, and inclusion of breakfast cereals fortified with vitamin B12 or use of vitamin B12 supplements offers additional protection.” An estimated 40 per cent of women and 13 per cent of men are at high risk of an osteoporotic fracture in their lifetime. When these fractures occur in older individuals, quality of life can decrease, sometimes dramatically.

Osteoporosis is also associated with higher mortality.

——————————————-

## Vitamin D :

# 13th Workshop on Vitamin D Victoria, British Columbia, April 7-12, 2006 http://vitamind.ucr.edu/current.html
from http://www.vitamindcouncil.com/

Understanding Vitamin D

Why all this excitement about vitamin D? We all know that vitamin D (cholecalciferol) is crucial to health. But is vitamin D really a vitamin? Is it in the foods humans normally consume? Please explore this web site and discover the amazing answers to these questions.

The high rate of natural production of vitamin D in the skin is the single most important fact every person should know about vitamin D because it has such profound implications for the natural human condition.

Healthcare Professionals: Now Available for Download:
THE CLINICAL IMPORTANCE OF VITAMIN D (CHOLECALCIFEROL): A PARADIGM SHIFT WITH IMPLICATIONS FOR ALL HEALTHCARE PROVIDERS
http://www.vitamindcouncil.com/PDFs/CME- clinicalImportanceVitD.pdf

Contributing authors:
Alex Vasquez DC ND, Gilbert Manso MD, and John Cannell MD

Vitamin D deficiency/insufficiency is an epidemic in the developed world that has heretofore received insufficient attention from clinicians despite documentation of its prevalence, consequences, and the imperative for daily supplementation at levels above the current inadequate recommendations of 200-600 IU.

– Utiger RD. The need for more vitamin D. N Engl J Med. 1998;338:828-9

Did you know?
# If you totally avoid the sun, recent research indicates you need about 4,000 units of vitamin D a day! So you can’t get enough vitamin D from milk (unless you drink 40 glasses a day) or from a multivitamin (unless you take about 10 tablets a day), neither of which is recommended.

# Most of us make about 20,000 units of vitamin D after about 20 minutes of summer sun. This is about 100 times more vitamin D than the government says you need every day.

# If you don’t get vitamin D the way Mother Nature intended, from sunshine, you need to take vitamin D supplements. As most of us get a lot more vitamin D from sunshine than we think, most of us need about 2,000 units a day extra.

# HEALTH NEWS Vitamin D Could Play a Role in Preventing Prostate Cancer http://health.dailynewscentral.com/content/view/1849/
Contributed by Nicole Weaver|02 November, 200500:22 GMT

Vitamin D may be useful in preventing prostate cancer, suggests a study presented today at the American Association for Cancer Research’s 4th annual Frontiers in Cancer Prevention Research meeting in Baltimore. ( http://www.aacr.org/ )

The active metabolite of vitamin D, calcitriol, and two other vitamin D analogs (QW-1624-F2-2 and paricalcitol) are promising chemopreventive agents, according to researchers from Roswell Park Cancer Institute.

They conducted both in vitro (outside the body) and in vivo (inside the body) studies to determine the effects of calcitriol and the analogs on the prevention of prostate cancer.

Inhibited Cell Growth

Calcitriol has been used clinically to treat a variety of disorders, including in recent clinical trials for established cancer.

However, a major obstacle to its clinical use is dose-limiting hypercalcemia — an abnormally high concentration of calcium in the blood. The Vitamin D analogs — QW, developed at John’s Hopkins University, and paricalcitol — are less calcemic.

QW and paricalcitol have been shown to reduce the level of parathyroid hormones, which regulate the metabolism of calcium and phosphorus in the body.

In their in vitro studies, the researchers demonstrated that the three drugs inhibit cell growth, inhibit DNA synthesis, and promote cell cycle arrest.

Additionally, the vitamin D compounds regulated several proteins that affect tumor growth.

Slowed Progression

The researchers then studied the effects of calcitriol and QW on preventing androgen-dependent prostate cancer in mice that were programmed using the TRAMP (transgenic adenocarcinoma of mouse prostate) model to develop the disease as they aged.

Both calcitriol and QW slowed the progression of prostate cancer in intact TRAMP mice after 14 weeks of treatment as indicated by decreased reproductive tract and prostate weight.

In addition, chronic treatment of mice with calcitriol markedly reduced tumor burden, but side effects were seen in some mice.

The effect of calcitriol and QW on hormone refractory prostate cancer also was investigated using castrated TRAMP mice. Results showed that vitamin D had no effect on disease progression in castrated mice as measured by reproductive tract and prostate weight.

Promising for Prevention

“Our pre-clinical data using the TRAMP mouse model, which mimics human prostate cancer, suggests that calcitriol and QW-1624-F2-2 are promising for prevention of androgen-dependent prostate cancer progression,” says Adebusola Alagbala of Roswell Park Cancer Institute and lead author of the study.

“Further studies are under way in our laboratory to better understand how these agents prevent prostate cancer,” Alagbala notes.

The studies, funded by the National Institutes of Health ( http://www.nih.gov/ ), were conducted in the laboratory of Dr. Barbara A. Foster at Roswell Park Cancer Institute.

Related Articles
– Sun Exposure Lessens Prostate Cancer Risk (15 Jun 2005) http://health.dailynewscentral.com/content/view/1056/63
– Sunshine May Ward Off Cancer (24 May 2005) http://health.dailynewscentral.com/content/view/827/63
– More Vitamin D for Everyone, Cancer Researchers Urge (14 Jan 2006) http://health.dailynewscentral.com/content/view/2054/77
– Report: Prostate Cancer Treatment Requires Team Approach (23 Sep 2004) http://health.dailynewscentral.com/content/view/37/63
– Sunshine Is Good for Us Again (22 May 2005) http://health.dailynewscentral.com/content/view/815/62
– Vitamin D Can Reduce Winter Depression (9 Jan 2006) http://health.dailynewscentral.com/content/view/2040/63

——————————————-